Neurodevelopmental Stimulation of a Child with a Noonan Syndrome with a Non-Frequent Mutation in RAF1 Gene — Case Report

Introduction. Noonan syndrome (NS) is a genetically determined disease, inherited from autosomal dominant. About 50% of patients have a mutation in the PTPN11 gene, and mutations in the other genes are much less frequent, up to 10–15% for SOS1, RAF1, and RIT1, as well as up to 1–2% for others. Aim. To present the clinical picture of a child with NS with a non-frequent mutation in the RAF1 gene and to describe a proposal of good practice based on the multi-specialty child care procedures used from birth to 3 years of age. Case Report. The paper presents a boy with NS and his psychomotor and linguistic development during the 36 months of his life. The infant was born by cesarean section in average general condition and with features of macrosomia. Castillo-Morales rehabilitation techniques were used to improve the coordination of suction, swallowing and breathing. Bobath Neurodevelopmental Treatment was also used on the hospital ward. The NS child’s development was assessed using the Munich Functional Developmental Diagnostics (MFDD). At the age of 36 months, the boy presents psychomotor development appropriate for the age of a healthy child. He remains under multidisciplinary team care and is intensively rehabilitated accordingly to both movement and linguistic functions. Discussion. Management of NS should be comprehensive and multidisciplinary, and continuous monitoring of patients is crucial. Although a number of patients experience learning difficulties and a mild form of mental impairment, the diagnosis of NS does not predispose to mental disorders. Conclusions. NS is a multi-symptomatic disease that manifests itself in the expression of clinical symptoms requiring the interdisciplinary cooperation of many specialists. The fact is that the identified mutation in the RAF1 gene in patients with NS does not mean they are predestined to develop psychomotor disorders. (JNNN 2019;8(2):78–85)

[1]  M. Marble,et al.  RAF1 variants causing biventricular hypertrophic cardiomyopathy in two preterm infants: further phenotypic delineation and review of literature. , 2017, Clinical dysmorphology.

[2]  M. Abbaszadegan,et al.  Noonan syndrome – a new survey , 2016, Archives of medical science : AMS.

[3]  A. Elhan,et al.  The Growth Characteristics of Patients with Noonan Syndrome: Results of Three Years of Growth Hormone Treatment: A Nationwide Multicenter Study , 2016, Journal of clinical research in pediatric endocrinology.

[4]  W. Helland,et al.  Pragmatic language impairment in children with Noonan syndrome , 2016, Clinical linguistics & phonetics.

[5]  R. Kessels,et al.  Intellectual development in Noonan syndrome: a longitudinal study , 2016, Brain and behavior.

[6]  A. Křepelová,et al.  A novel heterozygous RIT1 mutation in a patient with Noonan syndrome, leukopenia, and transient myeloproliferation—a review of the literature , 2016, European Journal of Pediatrics.

[7]  O. Migita,et al.  Spectrum of mutations and genotype–phenotype analysis in Noonan syndrome patients with RIT1 mutations , 2016, Human Genetics.

[8]  R. Kessels,et al.  Alexithymia, emotion perception, and social assertiveness in adult women with Noonan and Turner syndromes , 2015, American journal of medical genetics. Part A.

[9]  E. Obersztyn,et al.  The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes. , 2014, Developmental period medicine.

[10]  Tiziana Franchin,et al.  Diagnosis of Noonan syndrome and related disorders using target next generation sequencing , 2014, BMC Medical Genetics.

[11]  A. Hlavatá,et al.  Rasopathies - dysmorphic syndromes with short stature and risk of malignancy. , 2013, Endocrine Regulations.

[12]  A. Pereira,et al.  Growth standards of patients with Noonan and Noonan‐like syndromes with mutations in the RAS/MAPK pathway , 2012, American journal of medical genetics. Part A.

[13]  W. Verhoeven,et al.  Cognitive functioning of adults with Noonan syndrome: a case–control study , 2012, Genes, brain, and behavior.

[14]  J. Allanson,et al.  Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines , 2010, Pediatrics.

[15]  Mark S. Seidenberg,et al.  The language phenotype of children and adolescents with Noonan syndrome. , 2010, Journal of speech, language, and hearing research : JSLHR.

[16]  K. Rauen,et al.  Noonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway , 2008, Expert Reviews in Molecular Medicine.

[17]  M. Pąchalska,et al.  Diagnosis of severe developmental disorders in children under three years of age. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[18]  Wendy Schackwitz,et al.  Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome , 2006, Nature Genetics.

[19]  M. Gos,et al.  [RAS/MAPK signal transduction pathway and its role in the pathogenesis of Noonan syndrome]. , 2012, Postepy biochemii.

[20]  P. Sullivan Gastrointestinal disorders in children with neurodevelopmental disabilities. , 2008, Developmental disabilities research reviews.